CN113699103A - Induced reinforcement preparation process and application of poultry mesenchymal stem cell exosomes - Google Patents
Induced reinforcement preparation process and application of poultry mesenchymal stem cell exosomes Download PDFInfo
- Publication number
- CN113699103A CN113699103A CN202110794777.XA CN202110794777A CN113699103A CN 113699103 A CN113699103 A CN 113699103A CN 202110794777 A CN202110794777 A CN 202110794777A CN 113699103 A CN113699103 A CN 113699103A
- Authority
- CN
- China
- Prior art keywords
- mesenchymal stem
- curcumin
- exosome
- poultry
- exosomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 92
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 54
- 244000144977 poultry Species 0.000 title claims abstract description 40
- 230000002787 reinforcement Effects 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 12
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 88
- 229940109262 curcumin Drugs 0.000 claims abstract description 44
- 235000012754 curcumin Nutrition 0.000 claims abstract description 44
- 239000004148 curcumin Substances 0.000 claims abstract description 44
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000000243 solution Substances 0.000 claims abstract description 41
- 210000004027 cell Anatomy 0.000 claims abstract description 32
- 230000010261 cell growth Effects 0.000 claims abstract description 16
- 241000271566 Aves Species 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 230000001954 sterilising effect Effects 0.000 claims abstract description 10
- 238000012258 culturing Methods 0.000 claims abstract description 8
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 239000006228 supernatant Substances 0.000 claims abstract description 8
- 239000008055 phosphate buffer solution Substances 0.000 claims abstract description 7
- 230000000638 stimulation Effects 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 26
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 13
- 238000004108 freeze drying Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 210000000130 stem cell Anatomy 0.000 claims description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 9
- 229930182555 Penicillin Natural products 0.000 claims description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- 229940049954 penicillin Drugs 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 229960005322 streptomycin Drugs 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 7
- 239000012894 fetal calf serum Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000000844 anti-bacterial effect Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 6
- 239000012498 ultrapure water Substances 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 229910001610 cryolite Inorganic materials 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 238000009295 crossflow filtration Methods 0.000 claims description 3
- 239000012510 hollow fiber Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000012847 fine chemical Substances 0.000 claims description 2
- 230000002087 whitening effect Effects 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 239000001963 growth medium Substances 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 2
- 239000004017 serum-free culture medium Substances 0.000 abstract 2
- 239000013078 crystal Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000000495 cryogel Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000000442 hair follicle cell Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000013094 purity test Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- MHMCOSLCKPWGQG-UHFFFAOYSA-H [U+6].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O Chemical compound [U+6].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O MHMCOSLCKPWGQG-UHFFFAOYSA-H 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a process for preparing an induced aid of an avian mesenchymal stem cell exosome, which comprises the following steps: performing primary separation culture on the poultry mesenchymal stem cells, performing subculture, taking the poultry mesenchymal stem cells, culturing by using a cell growth medium, discarding the culture medium, washing the cells for three times by using a phosphate buffer solution, adding curcumin for stimulation, continuously culturing for 72 hours by using a serum-free culture medium, collecting the serum-free culture medium, and continuously performing the treatment on the cells which are not collected until a sufficient amount of supernatant is collected; centrifuging the collected curcumin-stimulated serum-free culture solution, extracting and concentrating the exosome filtrate, and sterilizing the obtained exosome concentrated filtrate. The invention stimulates and induces poultry mesenchymal stem cells by curcumin through improving the process formula, promotes the production of exosomes boosted by curcumin, and has more excellent effect compared with exosomes without the boosting effect of curcumin.
Description
Technical Field
The invention relates to a preparation method of stem cell exosomes, in particular to a preparation process and application of induced aid of avian mesenchymal stem cell exosomes, and belongs to the technical field of stem cell biomedicines.
Background
The source of the poultry mesenchymal stem cells is wide, the materials are easy to obtain, the cell separation efficiency is high, the cell strain state is stable, and the medical ethical problem does not exist, so that the poultry mesenchymal stem cells are gradually paid attention to. Exosomes are nanoscale vesicles that are released outside of a cell upon environmental stimulation or activation of the cell. Vesicle structures are classified into 3 types according to their diameter: exosomes (diameter 40-150 nm), microvesicles (diameter 100-1000 nm) and apoptotic bodies (diameter 1-4 μm). The exosome is formed by gathering substances such as protein, DNA (deoxyribonucleic acid) fragments, miRNA (micro ribonucleic acid) and the like in cytoplasm into a multi-vesicle endosome through an endocytosis path, and then fusing and cracking the multi-vesicle and a plasma membrane to release the multi-vesicle endosome to the outside of cells to form the exosome. The internal structure of exosomes mainly depends on the cell from which they are derived, but most exosomes are rich in integrins, heat shock proteins, the tetraspanin superfamily (CD9, CD63, CD81 and CD82), the cell endogenous proteins alix and the Rab protein family, and these proteins can be used as reliable markers for identifying exosomes.
Exosomes have functions of helping to remove old and useless cells and substituting with new cells, and are regarded as important substances effective in combating the aging and repair of skin. In addition to the development of applications at the beauty end, it was also found that exosomes also have an improving effect on allergic rhinitis caused by air pollution or seasonal alternation. If the exosome is prepared into an inhalation spray type, and is inhaled through the nasal cavity and the oral cavity, the exosome can pass through the nasal mucosa, the inflammatory reaction at the nasal mucosa is relieved, and the symptoms of nasal obstruction, rhinorrhea, asthma and the like are improved.
At present, although studies have been made on the use of specific induction conditions for inducing stem cells to secrete supernatants in vitro for medical treatment, cosmetics and the like, these conditioned media achieve therapeutic effects by inducing stem cells to secrete certain specific factors using specific cytokines, and the cytokines themselves are expensive, which results in an abnormally high cost of application of stem cells.
Disclosure of Invention
The technical problem to be solved by the invention is to overcome the defects of the prior art and provide an induced reinforcement preparation process and application of the poultry mesenchymal stem cell exosomes, wherein curcumin is used for stimulating and inducing poultry mesenchymal stem cells to promote the production of exosomes reinforced by curcumin, and the effect of the exosomes is more excellent than that of exosomes not reinforced by curcumin.
In order to solve the technical problems, the invention provides a process for preparing an induced aid of an avian mesenchymal stem cell exosome, which comprises the following steps:
s1: carrying out primary isolation culture on the poultry mesenchymal stem cells, carrying out subculture, and taking subcultured P3-P30 generation human adipose mesenchymal stem cells;
s2: culturing with cell growth liquid until 75-85% of cells are fused, discarding the culture liquid, washing the cells with phosphate buffer solution for three times, adding curcumin, culturing with serum-free culture liquid for 72 hr, and collecting the serum-free culture liquid;
s3: continuing the curcumin stimulation treatment of the step until the serum-free culture solution is collected, wherein the cells which are not collected in the step S2 are not collected;
s4: collecting serum-free culture solution stimulated by curcumin in the steps S2 and S3, centrifuging, extracting and concentrating the exosome filtrate, and finally preparing the needed curcumin to induce the reinforcement poultry mesenchymal stem cell exosomes after degerming treatment is carried out on the obtained exosome concentrated filtrate;
s5: adding excipient and water into curcumin-induced aid-increasing poultry mesenchymal stem cell exosome, mixing, filtering for sterilization, and freeze-drying to obtain the stem cell extract freeze-dried powder.
Although the curcumin-induced reinforcement poultry mesenchymal stem cell exosome has various biological activities and is wide in application field, the biological activities of the curcumin-induced reinforcement poultry mesenchymal stem cell exosome are limited by various external conditions and are inconvenient to store, so that the invention also provides the cryolite powder of the curcumin-induced reinforcement poultry mesenchymal stem cell exosome, and the cryolite powder is prepared by the cryolite powder preparation method commonly used in the field; the frozen crystal powder is prepared by freezing liquid medicine into solid state in aseptic environment, and then carrying out vacuum pumping to sublimate and dry water.
In a further limited technical scheme of the present invention, in the induced rescue preparation process of the poultry mesenchymal stem cell exosome, the cell growth solution is a DMEM culture solution containing 5% fetal bovine serum, and the culture solution further contains an antibacterial antibiotic; the antibacterial antibiotic is penicillin and streptomycin, wherein the final concentration of penicillin in a cell growth solution is 200U/ml, the final concentration of streptomycin in the cell growth solution is 250U/ml, the DMEM culture solution containing 5% fetal calf serum is obtained by adding 5% of fetal calf serum into a commercially available basic DMEM culture solution, and the penicillin with the final concentration of 200U/ml and the streptomycin with the final concentration of 250U/ml are added to obtain the cell growth solution.
In the induced reinforcement preparation process of the poultry mesenchymal stem cell exosomes, the phosphate buffer solution is a PBS solution with a pH value of 7.0-7.2; the excipient is any one of mannitol, trehalose or sucrose; the dosage of the excipient accounts for 5-10% of the total weight of the curcumin-induced reinforcement poultry mesenchymal stem cell exosomes.
In the induced reinforcement preparation process of the poultry mesenchymal stem cell exosomes, the water in the step S5 is ultrapure water, and the ultrapure water is added to a final volume of 100 ml; the freeze-drying treatment is that the freeze-drying temperature is-20 to-35 ℃, the vacuum degree is 50 to 200Pa, and the freeze-drying is carried out for 48 hours.
Further, in the aforementioned induced aid preparation process of the poultry mesenchymal stem cell exosomes, the centrifugation in step S4 is performed for 1,000xg10 minutes and 10,000xg10 minutes, after that, the supernatant is collected, the collected supernatant is subjected to tangential flow filtration through a hollow fiber membrane, the collected, filtered and concentrated exosome solution is then passed through an exosome extraction system to extract a high-purity exosome solution, and the sterilization treatment is performed by filtering and sterilizing through a sterile 0.22 μm filter membrane.
An application of fowl mesenchymal stem cell exosome comprises preparing wound healing medicine or cell repairing medicine from stem cell extract cryo-crystal powder; preparing a whitening product or a fine chemical product for resisting skin wrinkles.
The invention has the beneficial effects that: according to the invention, through improvement of a process formula, poultry mesenchymal stem cells are stimulated and induced by curcumin, and exosomes boosted by curcumin are promoted to be generated, so that the effect of the exosomes is more excellent than that of exosomes not boosted by curcumin; meanwhile, exosomes secreted by the isolated cells are collected and extracted by a special technology, and are called curcumin-induced reinforcement poultry mesenchymal stem cell exosomes; the curcumin induces the exosomes of the mesenchymal stem cells of the booster poultry to be frozen and dried to produce frozen crystal powder, thereby ensuring the biological activity and the efficacy. The process verified by the invention is mainly to discuss the effect of curcumin induced enhancement poultry mesenchymal stem cell exosome on skin repair.
Drawings
FIG. 1 is a transmission electron microscope image of the present invention before and after lyophilization.
FIG. 2 shows particle size analysis and particle number according to the present invention.
FIG. 3 shows the purity test of the frozen crystal powder of the present invention.
FIG. 4 shows the protein concentration contained in the frozen powder of the present invention.
FIG. 5 shows the RNA concentration of exosomes contained in the cryogel powder of the present invention.
FIG. 6 shows the cell proliferation effect of the cryo-crystal powder of the present invention on human skin fibroblasts.
FIG. 7 shows the effect of cryo-crystal powder of the present invention on cell proliferation of human hair follicle cells.
FIG. 8 is a graph showing the wound healing effect of the cryo-crystal powder of the present invention on human skin fibroblasts.
Detailed Description
The induced reinforcement preparation process of the poultry mesenchymal stem cell exosome provided by the embodiment comprises the following steps:
s1: carrying out primary isolation culture on the poultry mesenchymal stem cells, carrying out subculture, and taking subcultured P3-P30 generation human adipose mesenchymal stem cells;
s2: culturing with cell growth liquid until 75-85% of cells are fused, discarding the culture liquid, washing the cells with phosphate buffer solution for three times, adding curcumin, culturing with serum-free culture liquid for 72 hr, and collecting the serum-free culture liquid;
s3: continuing the curcumin stimulation treatment of the step until the serum-free culture solution is collected, wherein the cells which are not collected in the step S2 are not collected;
s4: collecting serum-free culture solution stimulated by curcumin in the steps S2 and S3, centrifuging, extracting and concentrating the exosome filtrate, and finally preparing the needed curcumin to induce the reinforcement poultry mesenchymal stem cell exosomes after degerming treatment is carried out on the obtained exosome concentrated filtrate; the centrifugation operation adopts the centrifugation process of 1,000Xg10 minutes and 10,000Xg10 minutes, the supernatant is collected after the centrifugation is finished, the collected supernatant flows through a hollow fiber membrane to be subjected to tangential flow filtration, the collected, filtered and concentrated exosome solution is then passed through an exosome extraction system to extract high-purity exosome solution, and the sterilization treatment adopts a sterile 0.22 mu m filter membrane to carry out filtration sterilization;
s5: adding excipient and ultrapure water into curcumin-induced aid-increasing poultry mesenchymal stem cell exosomes, mixing, filtering for sterilization, and then performing freeze-drying treatment to obtain stem cell extract freeze-dried powder; adding ultrapure water to a final volume of 100 ml; the freeze-drying treatment is that the freeze-drying temperature is-20 to-35 ℃, the vacuum degree is 50 to 200Pa, and the freeze-drying is carried out for 48 hours.
The cell growth medium in this example is DMEM medium containing 5% fetal bovine serum, and the culture medium further contains an antibacterial antibiotic; the antibacterial antibiotic is penicillin and streptomycin, wherein the final concentration of penicillin in the cell growth solution is 200U/ml, the final concentration of streptomycin in the cell growth solution is 250U/ml, and the DMEM culture solution containing 5% fetal calf serum is obtained by adding 5% fetal calf serum to a commercially available basic DMEM culture solution, and adding penicillin with the final concentration of 200U/ml and streptomycin with the final concentration of 250U/ml to obtain the cell growth solution. The phosphate buffer solution is a PBS solution with the pH value of 7.0-7.2; the excipient is any one of mannitol, trehalose or sucrose; the dosage of the excipient accounts for 5-10% of the total weight of the curcumin-induced reinforcement poultry mesenchymal stem cell exosomes.
Reagent instruments are used in this example:
BCA protein detection kit: # 23225; thermo Fisher Scientific, Waltham, MA, USA;
RIPA buffer: 50 mM Tris-HCl, pH7.4, 150 mM NaCl, 1% Triton X-100, 1% Na-deoxyholate, 0.1% SDS, 0.1 mM CaCl2, and 0.01 mM MgCl2;
qEV RNA extraction kit: IZON Science LTD, Christchurch, New Zealand;
protease inhibitor cocktail: thermo Fisher Scientific;
full wavelength microplate reader: molecular Devices, San Jose, Calif., USA;
HitachiHT7700 electron microscope: hitachi, Tokyo, Japan;
a spectral luminance meter: NanoDrop ™ 2000c, Thermo Fisher Scientific;
silica gel insert: culture inserts, 2-well plates, ibiTreat; ibidi, Martinsried, Germany.
Transmission electron microscope using procedure
Curcumin-induced enhancement poultry mesenchymal stem cell exosome frozen crystal powder samples are prepared for transmission electron microscopy. Briefly, exosomes were immobilized on copper mesh, fixed with 1% glutaraldehyde in cold PBS for 5 min to stabilize the immune response, washed with sterile distilled water, compared with a uranium oxalate solution at pH7 for 5 min, and then embedded with methylcellulose on ice for 10 min. Excess cellulose was removed and the samples were dried for permanent storage. The exosome samples were imaged using a HitachiHT7700 electron microscope at 80kV voltage.
Detection of contaminating heteroprotein
The pierce tmbca protein assay kit was used for purity testing. A standard curve (range 0-2000. mu.g/mL) was obtained from nine serial dilutions of Bovine Serum Albumin (BSA) and working reagent. All samples and standard spots were repeated 3 times. Dissolving samples (10 μ l each) (100 mg curcumin-induced rescue poultry mesenchymal stem cell exosome freeze-dried powder or freeze-dried powder of control exosome in 500 μ lQH2O) was mixed with 200 μ l of the working reagent and incubated at 65 ℃ for 30 minutes. After cooling to room temperature, each difference in absorbance (minus the average absorbance of the 562nm blank standard replicate) was measured by a full wavelength microplate reader and converted to μ g/ml through standard curve. If the protein concentration exceeds the upper limit of the standard curve, 2000. mu.g/mL, the sample is diluted to a level that can be determined within the standard range and the final concentrate is calibrated to take into account the dilution factor.
Exosome protein concentration detection step curcumin induces the frozen crystal powder of the exosomes of the rescue poultry interstitial stem cells of 100mg and the frozen crystal powder of the control exosomes to be resuspended in RIPA buffer solution and supplemented with protease inhibitor mixture. The BCA protein assay kit was used for purity testing. Nine serial dilutions were made using Bovine Serum Albumin (BSA) and working reagent to generate a standard curve (range 0-250. mu.g/mL). All samples and standard spots were repeated 3 times. Samples (10. mu.l each) were mixed with 200. mu.l of working reagent and incubated at 65 ℃ for 30 minutes. After cooling to room temperature, each difference in absorbance was measured by a full wavelength microplate reader, the average absorbance at 562nm of the blank standard replicate was subtracted, and the difference in absorbance was converted to μ g/ml by the standard curve.
Exosome RNA concentration detection
Curcumin induces the frozen crystal powder of the exosomes of the enhancement poultry mesenchymal stem cells of 100mg and the frozen crystal powder of the exosomes of 100mg are resuspended in the lysis buffer A of the qEVRNA extraction kit. The detailed extraction method follows the user specification. And detecting the RNA concentrations of the extracted exosomes of the curcumin-induced enhancement poultry interstitial stem cell exosome frozen crystal powder and the control exosomes by using a spectrophotometer.
Cell proliferation assay procedure
To determine cell viability, human skin fibroblasts and human hair follicle cells were cultured in their growth media until they reached 80% density. Cells were treated at 5X 103The total volume of individual cells per well was seeded in 96-well plates at a density of 100 μ l. After inoculation, cells were incubated at 37 ℃ and 5% CO2Medium for 24 hours to allow cell attachment. Cells were then washed once with PBS and the medium was replaced with medium containing 0.25% stripped FBS, starved for 24 hours. Supplemented with curcumin-induced rescue-enhancing avian mesenchymal stem cell exosome cryogels at different concentrations and medium containing 0.25% stripped FBS and treated for 72 hours (human dermal fibroblasts) or 96 hours (human hair follicle cells). Curcumin induces the supplement poultry interstitial stem cell exosome frozen crystal powder culture medium mixture to be renewed every other day. After 72 hours or 96 hours of treatment, the medium containing 20% MTS solution was changed to growth medium and incubated for 2 hours. The absorbance at 490nm was measured for each well using a full wavelength microplate reader.
Procedure for wound healing test
To examine the wound healing effect of curcumin-induced enhancement of avian mesenchymal stem cell exosome cryogel powder on the treatment of human dermal fibroblasts, a wound healing experiment was performed using a silica gel insert, and cells were plated in 24-well plates. Specifically, the cells were incubated at 2.5X 105 cells/cm2Is seeded in two compartments of a silica gel insert. The cells were grown for 24 hours, then the medium was changed to starvation medium (no serum) and cultured for another 24 hours. The culture inserts were removed using sterile forceps, creating a 500 μm wide gap. Media supplemented with curcumin-induced rescue avian mesenchymal stem cell exosome cryogels at different concentrations and 0.25% stripped FBS were added and incubated for 24 hours.
In addition to the above embodiments, the present invention may have other embodiments. All technical solutions formed by adopting equivalent substitutions or equivalent transformations fall within the protection scope of the claims of the present invention.
Claims (8)
1. An induced reinforcement preparation process of an avian mesenchymal stem cell exosome is characterized by comprising the following steps:
s1: carrying out primary isolation culture on the poultry mesenchymal stem cells, carrying out subculture, and taking subcultured P3-P30 generation human adipose mesenchymal stem cells;
s2: culturing with cell growth liquid until 75-85% of cells are fused, discarding the culture liquid, washing the cells with phosphate buffer solution for three times, adding curcumin, culturing with serum-free culture liquid for 72 hr, and collecting the serum-free culture liquid;
s3: continuing the curcumin stimulation treatment of the step until the serum-free culture solution is collected, wherein the cells which are not collected in the step S2 are not collected;
s4: collecting serum-free culture solution stimulated by curcumin in the steps S2 and S3, centrifuging, extracting and concentrating the exosome filtrate, and finally preparing the needed curcumin to induce the reinforcement poultry mesenchymal stem cell exosomes after degerming treatment is carried out on the obtained exosome concentrated filtrate;
s5: adding excipient and water into curcumin-induced aid-increasing poultry mesenchymal stem cell exosome, mixing, filtering for sterilization, and freeze-drying to obtain the stem cell extract freeze-dried powder.
2. The process for preparing exosomes of avian mesenchymal stem cells according to claim 1, wherein: the cell growth solution is DMEM culture solution containing 5% fetal calf serum, and the culture solution also contains antibacterial antibiotics; the antibacterial antibiotic is penicillin and streptomycin, wherein the final concentration of penicillin in a cell growth solution is 200U/ml, the final concentration of streptomycin in the cell growth solution is 250U/ml, the DMEM culture solution containing 5% fetal calf serum is obtained by adding 5% of fetal calf serum into a commercially available basic DMEM culture solution, and the penicillin with the final concentration of 200U/ml and the streptomycin with the final concentration of 250U/ml are added to obtain the cell growth solution.
3. The process for preparing exosomes of avian mesenchymal stem cells according to claim 1, wherein: the phosphate buffer solution is a PBS solution with the pH value of 7.0-7.2.
4. The process for preparing exosomes of avian mesenchymal stem cells according to claim 1, wherein: the excipient is any one of mannitol, trehalose or sucrose; the dosage of the excipient accounts for 5-10% of the total weight of the curcumin-induced reinforcement poultry mesenchymal stem cell exosomes.
5. The process for preparing exosomes of avian mesenchymal stem cells according to claim 1, wherein: the water in the step S5 is ultrapure water, and ultrapure water is added to a final volume of 100 ml.
6. The process for preparing exosomes of avian mesenchymal stem cells according to claim 1, wherein: the freeze-drying treatment is that the freeze-drying temperature is-20 to-35 ℃, the vacuum degree is 50 to 200Pa, and the freeze-drying is carried out for 48 hours.
7. The process for preparing exosomes of avian mesenchymal stem cells according to claim 1, wherein:
the centrifugation operation of the step S4 is to adopt the centrifugation process of 1,000Xg10 minutes and 10,000Xg10 minutes, collect the supernatant after the centrifugation is finished, flow the collected supernatant through the hollow fiber membrane to carry out tangential flow filtration, collect the filtered and concentrated exosome solution and then pass through an exosome extraction system to extract the high-purity exosome solution, and the sterilization treatment adopts a sterile 0.22 mu m filter membrane to carry out filtration sterilization.
8. The application of the poultry mesenchymal stem cell exosome is characterized in that: preparing a wound healing medicament or a cell repairing medicament by using the stem cell extract cryolite powder; preparing a whitening product or a fine chemical product for resisting skin wrinkles.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110794777.XA CN113699103B (en) | 2021-07-14 | 2021-07-14 | Preparation process and application of induced enhancement of exosomes of mesenchymal stem cells of birds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110794777.XA CN113699103B (en) | 2021-07-14 | 2021-07-14 | Preparation process and application of induced enhancement of exosomes of mesenchymal stem cells of birds |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113699103A true CN113699103A (en) | 2021-11-26 |
CN113699103B CN113699103B (en) | 2023-04-25 |
Family
ID=78648644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110794777.XA Active CN113699103B (en) | 2021-07-14 | 2021-07-14 | Preparation process and application of induced enhancement of exosomes of mesenchymal stem cells of birds |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113699103B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117721070A (en) * | 2024-02-07 | 2024-03-19 | 国典(北京)医药科技有限公司 | Method for detecting purity of hiPSC source exosome and special digestive agent thereof |
JP7453705B2 (en) | 2022-02-14 | 2024-03-21 | 陞醫生物科技股▲分▼有限公司 | Exosomes and their preparation process and their use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103784474A (en) * | 2014-01-26 | 2014-05-14 | 广州赛莱拉生物科技有限公司 | Human fat mesenchymal stem cell extract and lyophilized powder and application thereof |
CN108451887A (en) * | 2018-03-27 | 2018-08-28 | 深圳市兰亭科技股份有限公司 | The skin care compositions and methods and application thereof of the body of excretion containing stem cell source |
CN109097326A (en) * | 2018-08-10 | 2018-12-28 | 广东唯泰生物科技有限公司 | A kind of method and its application preparing mescenchymal stem cell excretion body |
-
2021
- 2021-07-14 CN CN202110794777.XA patent/CN113699103B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103784474A (en) * | 2014-01-26 | 2014-05-14 | 广州赛莱拉生物科技有限公司 | Human fat mesenchymal stem cell extract and lyophilized powder and application thereof |
CN108451887A (en) * | 2018-03-27 | 2018-08-28 | 深圳市兰亭科技股份有限公司 | The skin care compositions and methods and application thereof of the body of excretion containing stem cell source |
CN109097326A (en) * | 2018-08-10 | 2018-12-28 | 广东唯泰生物科技有限公司 | A kind of method and its application preparing mescenchymal stem cell excretion body |
Non-Patent Citations (1)
Title |
---|
刘金伟: "人脂肪间充质干细胞外泌体通过上调β-catenin、c-Myc和细胞周期蛋白表达促进表皮干细胞增殖" * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7453705B2 (en) | 2022-02-14 | 2024-03-21 | 陞醫生物科技股▲分▼有限公司 | Exosomes and their preparation process and their use |
CN117721070A (en) * | 2024-02-07 | 2024-03-19 | 国典(北京)医药科技有限公司 | Method for detecting purity of hiPSC source exosome and special digestive agent thereof |
CN117721070B (en) * | 2024-02-07 | 2024-05-10 | 国典(北京)医药科技有限公司 | Method for detecting purity of hiPSC source exosome and special digestive agent thereof |
Also Published As
Publication number | Publication date |
---|---|
CN113699103B (en) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109536440A (en) | The extracting method of excretion body | |
JP2019517488A (en) | Human platelet lysate-derived extracellular vesicles for use in medicine | |
CN111249449B (en) | Extracellular vesicle-interleukin-10 nano targeted drug and preparation method and application thereof | |
CN113699103A (en) | Induced reinforcement preparation process and application of poultry mesenchymal stem cell exosomes | |
CN114591905B (en) | Method for preparing apoptotic vesicles from human erythrocytes and application of apoptotic vesicles | |
JP2010538681A (en) | Methods for extracting mesenchymal stem cells from human or animal embryos and their secretions | |
CN114306384B (en) | Application of human platelet apoptosis microvesicle | |
CN108715830A (en) | Urinate extracting method and its application of derived stem cell excretion body | |
CN113321709A (en) | Self-assembled polypeptide, slow-release exosome polypeptide hydrogel and preparation method and application thereof | |
CN116024157A (en) | Preparation method of ginger exosomes | |
CN114874981A (en) | Mesenchymal stem cell exosome and application thereof in immune cell culture | |
CN102747033A (en) | Method for culturing mesenchymal stem cells and fibroblast tissue from gingival tissue | |
CN109200011A (en) | A kind of skin care item and preparation method thereof | |
CN116064387A (en) | Preparation and application of epimedium vesicles | |
CN116496971A (en) | Mugwort leaf-derived exosome-like nano vesicle and application and medicament thereof | |
CN114652703B (en) | Application of aerosol inhalation functional extracellular vesicles in improving acute lung injury | |
RU2710368C2 (en) | METHOD OF PRODUCING AND CONCENTRATING microRNA-CONTAINING EXOSOMES OF MULTIPOTENT MESENCHYMAL STROMAL CELLS FOR USE IN COSMETIC AND MEDICINAL AGENTS FOR STIMULATING REGENERATIVE PROCESSES AND SLOWING DOWN AGING PROCESSES | |
KR102424333B1 (en) | Method for mass production of high-purity extracellular vesicles derived from stem cells using peptides | |
JP6188249B2 (en) | Wound healing composition derived from porcine umbilical cord tissue, method for producing the same, and pharmaceutical product for wound healing containing the composition | |
JP2016079177A (en) | Composition which promotes growth of dermal papilla cell, method for manufacturing the same, and medicinal drug containing the composition | |
TWI828062B (en) | Methods for producing exosomes, the exosomes produced and their applications | |
CN117586955B (en) | Preparation and application of EPO-stimulated macrophage-derived exosome | |
AU2021106118A4 (en) | Use of microvesicle derived from umbilical cord mesenchymal stem cell in preparation of formulation for promoting regeneration of post-traumatic skin appendage | |
KR20200001370A (en) | Crushed Stem Cell Extract(Shelled Stem Cell) Manufacturing Method Using Mass Culture Medium Composition Method and Constituent 3-low Extracting Method and A Treating Composition for Anti-Inflammatory and A Treating Composition for Cell Regeneration | |
KR102563616B1 (en) | Soluble extracellular matrix derived from stem cells and preparing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231222 Address after: Taipei City, Taiwan, China Patentee after: Shengyi Biotechnology Co.,Ltd. Address before: Unit G1-1101-023, Artificial Intelligence Industrial Park, No. 88 Jinjihu Avenue, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215000 Patentee before: Xie Rusheng |
|
TR01 | Transfer of patent right |